| Ytd | -25.27% | |
| 1y | -70.92% |
| Open | 0.71 | Prev Close | 0.71 | Low | 0.70 | High | 0.74 | Mkt Cap | 120.66M |
| Vol | 2.26M | Avg Vol | 10.71M | EPS | -0.60 | P/E | -1.20 | Forward P/E | -5.41 |
| Beta | 1.47 | Short Ratio | 6.37 | Inst. Own | 30.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-10 | 50-d Avg | 0.90 | 200-d Avg | 1.04 | 1yr Est | 13.71 |
HUMA News
DURHAM, N.C., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.73, signifying a +2.33% move from i
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from i
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter
In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the
Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the
Humacyte, Inc. (HUMA) closed the most recent trading day at $0.71, moving +2.31% from the previous t
- Dr. Robert J. Kossmann has served as a prominent advocate for kidney disease patients in multiple
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
The latest trading day saw Humacyte, Inc. (HUMA) settling at $0.78, representing a -2.32% change fro
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous tr
Humacyte, Inc. (HUMA) Discusses V012 Study Top-Line Results for Engineered Vessel in Dialysis Access
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is r
– Positive results from the V012 Phase 3 study were presented at the Society for Vascular Surgery's
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi
DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage bi
- Humacyte plans to file a supplemental Biologic License Application (BLA) with the Food and Drug Ad
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Jun
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnin